Register for Free!
Pipeline includes preclinical development and Phase 2 clinical trials. The development may take years and may not gain regulatory approval or reach commercialization. To date, the company finances activity by selling shares, and dilution would be expected in the future to increase capital as necessary. Expenses will substantially increase in the event of pipeline expansion or in advancing clinical trials.
In the case of approval, expenses will rise to commercialize products. The main candidates G1T38 and G1T48 may achieve negative data or regulatory delays or failures. Conclusion Early biotech companies can rise ahead of important data and then fall after.
It is common for these companies to overshoot their valuation and then slip back. The ASCO data, while favorable, is still early.
Your feedback matters to us!
There are no near-term data catalysts that will take the share price higher. Traders that positioned ahead of the data will move out of this trade impacting share price. It is my opinion that the share price could pull back after ASCO until more data approaches. This is a favorable time to take profit from this stock, given the valuation overshoot.
The shares will have more favorable re-entry down the road. I wrote this article myself, and it expresses my own opinions. He has served on the boards of directors and scientific advisory boards of several biotechnology companies, including Intellikine, an oncology therapeutics company acquired by Takeda in Previously, he served as Vice President, Oncology Marketing for Astellas where he led several product launches.
He has worked for more than 20 years in oncology including roles of increasing leadership at Eli Lilly, Novartis, and Abbott. Demaree brings to G1 a strong history of building commercial capabilities and leading multiple successful new product and new indication launches. His areas of expertise include strategy, commercialization, new product launches, market access and reimbursement strategy, internal and external collaboration leadership, and business development and licensing. Hanson joined G1 as General Counsel in June In prior positions at Quintiles, Mr.